<DOC>
	<DOC>NCT00958152</DOC>
	<brief_summary>The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.</brief_summary>
	<brief_title>Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy males, and/or healthy females of nonchildbearing potential, aged 18 to 55 years (inclusive) Body mass index (BMI) between 18 and 31 kg/m2 (inclusive) and weight &gt; 50 kg Women of child bearing potential Subjects positive for Hepatitis B, Hepatitis C, or HIV Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>VX-950</keyword>
	<keyword>VX-222</keyword>
	<keyword>STAT-C</keyword>
</DOC>